RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use
US12365897B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 25, 2022 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | Dec 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Mucin 5AC (MUC5AC) gene. The MUC5AC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MUC5AC gene. Pharmaceutical compositions that include one or more MUC5AC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MUC5AC RNAi agents to pulmonary epithelial cells, in vivo, provides for inhibition of MUC5AC gene expression and a reduction in MUC5AC production, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including mucoobstructive lung disease such as severe asthma and various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.